Nothing Special   »   [go: up one dir, main page]

SE0002729D0 - Novel compound form - Google Patents

Novel compound form

Info

Publication number
SE0002729D0
SE0002729D0 SE0002729A SE0002729A SE0002729D0 SE 0002729 D0 SE0002729 D0 SE 0002729D0 SE 0002729 A SE0002729 A SE 0002729A SE 0002729 A SE0002729 A SE 0002729A SE 0002729 D0 SE0002729 D0 SE 0002729D0
Authority
SE
Sweden
Prior art keywords
naphtyl
methylpiperazin
tetrahydro
methyl
novel compound
Prior art date
Application number
SE0002729A
Other languages
English (en)
Inventor
Per-Olov Bergstroem
Martin Hedberg
Mona Lindstroem
Erica Staahle
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Priority to SE0002729A priority Critical patent/SE0002729D0/sv
Publication of SE0002729D0 publication Critical patent/SE0002729D0/sv
Priority to ARP010103259A priority patent/AR029588A1/es
Priority to KR10-2003-7000799A priority patent/KR20030015398A/ko
Priority to BR0112619-9A priority patent/BR0112619A/pt
Priority to CA002415046A priority patent/CA2415046A1/en
Priority to RU2002135626/04A priority patent/RU2002135626A/ru
Priority to AU7287201A priority patent/AU7287201A/xx
Priority to EP01952077A priority patent/EP1305303A1/en
Priority to EEP200300028A priority patent/EE200300028A/xx
Priority to US10/333,286 priority patent/US6706710B2/en
Priority to PL01365112A priority patent/PL365112A1/xx
Priority to MXPA03000439A priority patent/MXPA03000439A/es
Priority to NZ523528A priority patent/NZ523528A/en
Priority to AU2001272872A priority patent/AU2001272872B2/en
Priority to CZ2003140A priority patent/CZ2003140A3/cs
Priority to PCT/SE2001/001643 priority patent/WO2002008212A1/en
Priority to UA20021210561A priority patent/UA72333C2/uk
Priority to HU0301116A priority patent/HUP0301116A3/hu
Priority to SK73-2003A priority patent/SK732003A3/sk
Priority to CN01813106A priority patent/CN1443178A/zh
Priority to JP2002514118A priority patent/JP2004504390A/ja
Priority to IL15383601A priority patent/IL153836A0/xx
Priority to ZA200300129A priority patent/ZA200300129B/en
Priority to IS6679A priority patent/IS6679A/is
Priority to NO20030220A priority patent/NO20030220L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/135—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Diabetes (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Nutrition Science (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
SE0002729A 2000-07-20 2000-07-20 Novel compound form SE0002729D0 (sv)

Priority Applications (25)

Application Number Priority Date Filing Date Title
SE0002729A SE0002729D0 (sv) 2000-07-20 2000-07-20 Novel compound form
ARP010103259A AR029588A1 (es) 2000-07-20 2001-07-10 Nueva forma (r)-n-[5-metil-8-(4-metilpiperazina-1-il)-1,2,3,4-tetrahidro-2-naftil]-4-morfolinobenzamida
IL15383601A IL153836A0 (en) 2000-07-20 2001-07-17 Novel form of (r)-n-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide
PL01365112A PL365112A1 (en) 2000-07-20 2001-07-17 Novel form of (r)-n-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide
AU2001272872A AU2001272872B2 (en) 2000-07-20 2001-07-17 Novel form of (R)-N-(5-methyl-8-(4-methylpiperazin-1-YL)-1,2,3,4-tetrahydro -2-naphthyl)-4-morpholinobenzamide
CA002415046A CA2415046A1 (en) 2000-07-20 2001-07-17 Novel form of (r)-n-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide
RU2002135626/04A RU2002135626A (ru) 2000-07-20 2001-07-17 Новая форма (r)-n-[5метил-8-(4-метилпиперазин-1-ил)-1,2,3,4-тетрагидро-2-нафтил]-4-мор фолинобензамида
AU7287201A AU7287201A (en) 2000-07-20 2001-07-17 Novel form of (R)-N-(5-methyl-8-(4-methylpiperazin-1-YL)-1,2,3,4-tetrahydro-2-naphthyl)-4-morpholinobenzamide
EP01952077A EP1305303A1 (en) 2000-07-20 2001-07-17 NOVEL FORM OF (R)- i N /i - 5-METHYL-8-(4-METHYLPIPERAZIN-1-YL)-1,2,3,4-TETRAHYDRO-2-NAPHTHYL]-4-MORPHOLINOBENZAMIDE
EEP200300028A EE200300028A (et) 2000-07-20 2001-07-17 (R)-N-[5-metüül-8-(4-metüülpiperasiin-1-üül)-1,2,3,4-tetrahüdro-2-naftüül]-4-morfolin obensamiidi uus vorm, meetod selle saamiseks ning kasutamine
US10/333,286 US6706710B2 (en) 2000-07-20 2001-07-17 Form of (R)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide
KR10-2003-7000799A KR20030015398A (ko) 2000-07-20 2001-07-17 신규한 형태의(ｒ)-ｎ-[5-메틸-8-(4-메틸피페라진-1-일)-1,2,3,4-테트라하이드로-2-나프틸]-4-모르폴리노벤즈아미드
MXPA03000439A MXPA03000439A (es) 2000-07-20 2001-07-17 Nueva forma de (r)-n-(5-metil -8-(4-metilpiperazin -1-il) -1,2,3,4-tetrahidro-2-naftil) -4-morfolinobenzamida.
NZ523528A NZ523528A (en) 2000-07-20 2001-07-17 Novel form of (R)-N-[5-methyl-8-(4-methylpiperazin-1-YL)-1,2,3,4-tetrahydro-2-naphthyl}-4-morpholinobenzamide
BR0112619-9A BR0112619A (pt) 2000-07-20 2001-07-17 Composto, processo para a preparação do mesmo, formulação farmacêutica, uso de um composto, métodos para o tratamento de distúrbios mediados por 5-hidroxitriptamina, e de distúrbios no sistema nervoso central e/ou de bexiga hiperativa ou vasospasmo ou para o controle do crescimento de tumores
CZ2003140A CZ2003140A3 (cs) 2000-07-20 2001-07-17 Nová forma (R)-N-[5-methyl-8-(4-methylpiperazin-l-yl)-1,2,3,4-tetrahydro-2-naftyl]-4-morfolinobenzamidu
PCT/SE2001/001643 WO2002008212A1 (en) 2000-07-20 2001-07-17 Novel form of (r)-n-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide
UA20021210561A UA72333C2 (en) 2000-07-20 2001-07-17 Form(r)-n-[5-methyl-8-(4-methylpiperazine-1-yl)-1,2,3,4,-tetrahydro-2-naphthyl]-4-morfolinobenzamide
HU0301116A HUP0301116A3 (en) 2000-07-20 2001-07-17 Novel form of (r)-n-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide, process for its preparation and pharmaceutical composition containing it
SK73-2003A SK732003A3 (en) 2000-07-20 2001-07-17 Novel form of (R)-N-[5-methyl-8-(4-methylpiperazin-1-yl)- 1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide
CN01813106A CN1443178A (zh) 2000-07-20 2001-07-17 (r)－n－[5－甲基－8－(4－甲基哌嗪－1－基)－1,2,3,4－四氢－2－萘基]－4－吗啉代苯甲酰胺的新形态
JP2002514118A JP2004504390A (ja) 2000-07-20 2001-07-17 （ｒ）−ｎ−［５−メチル−８−（４−メチルピペラジン−１−イル）−１，２，３，４−テトラヒドロ−２−ナフチル］−４−モルホリノベンズアミドの新規な形態
ZA200300129A ZA200300129B (en) 2000-07-20 2003-01-06 Novel form of (R)-N-[5-methyl-8-(4-methylpiperazin-1-yl)-1,2,3,4-tetrahydro-2-naphthyl]-4-morpholinobenzamide.
IS6679A IS6679A (is) 2000-07-20 2003-01-14 Ný form (R)-N-[5-metýl-8-(4-metýlpíperasín-1-ýl)-1,2,3,4-tetrahýdró-2-naftýl]-4-morfólínóbensamíðs
NO20030220A NO20030220L (no) 2000-07-20 2003-01-16 Ny form av (R)-N-[5-metyl-8-(4-metylpiperazin-1-yl)-1,2,3,4- tetrahydro-2-naftyl]-4-morfolinobenzamid

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0002729A SE0002729D0 (sv) 2000-07-20 2000-07-20 Novel compound form

Publications (1)

Publication Number Publication Date
SE0002729D0 true SE0002729D0 (sv) 2000-07-20

Family

ID=20280557

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0002729A SE0002729D0 (sv) 2000-07-20 2000-07-20 Novel compound form

Country Status (24)

Country Link
US (1) US6706710B2 (sv)
EP (1) EP1305303A1 (sv)
JP (1) JP2004504390A (sv)
KR (1) KR20030015398A (sv)
CN (1) CN1443178A (sv)
AR (1) AR029588A1 (sv)
AU (2) AU7287201A (sv)
BR (1) BR0112619A (sv)
CA (1) CA2415046A1 (sv)
CZ (1) CZ2003140A3 (sv)
EE (1) EE200300028A (sv)
HU (1) HUP0301116A3 (sv)
IL (1) IL153836A0 (sv)
IS (1) IS6679A (sv)
MX (1) MXPA03000439A (sv)
NO (1) NO20030220L (sv)
NZ (1) NZ523528A (sv)
PL (1) PL365112A1 (sv)
RU (1) RU2002135626A (sv)
SE (1) SE0002729D0 (sv)
SK (1) SK732003A3 (sv)
UA (1) UA72333C2 (sv)
WO (1) WO2002008212A1 (sv)
ZA (1) ZA200300129B (sv)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY157518A (en) 2008-06-20 2016-06-15 Astrazeneca Ab Dibenzothiazepine derivatives and use thereof
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
CN105324372B (zh) 2013-06-21 2018-03-06 武田药品工业株式会社 作为前动力蛋白受体调节剂的1‑磺酰基哌啶衍生物
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
SE9900190D0 (sv) 1999-01-22 1999-01-22 Astra Ab New compounds
SE9702799D0 (sv) * 1997-07-25 1997-07-25 Astra Ab New compounds

Also Published As

Publication number Publication date
PL365112A1 (en) 2004-12-27
EE200300028A (et) 2004-10-15
CA2415046A1 (en) 2002-01-31
SK732003A3 (en) 2003-08-05
US20030166653A1 (en) 2003-09-04
US6706710B2 (en) 2004-03-16
WO2002008212A1 (en) 2002-01-31
NO20030220D0 (no) 2003-01-16
AU2001272872B2 (en) 2005-08-25
AU7287201A (en) 2002-02-05
AR029588A1 (es) 2003-07-02
JP2004504390A (ja) 2004-02-12
KR20030015398A (ko) 2003-02-20
IL153836A0 (en) 2003-07-31
RU2002135626A (ru) 2004-07-27
UA72333C2 (en) 2005-02-15
CZ2003140A3 (cs) 2003-06-18
BR0112619A (pt) 2003-07-29
IS6679A (is) 2003-01-14
HUP0301116A3 (en) 2006-03-28
CN1443178A (zh) 2003-09-17
EP1305303A1 (en) 2003-05-02
ZA200300129B (en) 2004-06-25
MXPA03000439A (es) 2003-06-24
HUP0301116A2 (hu) 2003-08-28
NZ523528A (en) 2004-09-24
NO20030220L (no) 2003-03-14

Similar Documents

Publication Publication Date Title
BR0210122A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, método para o tratamento ou prevenção de uma doença, uso do composto ou de seu sal, e, método para preparar o mesmo
DE60005054D1 (de) Chinuclidin-acrylamide
JO2371B1 (en) 4-phenyl-pyridine derivatives
AP1818A (en) Urea-compounds active as vanilloid receptor antagonists for the treatment of pain
GB0112348D0 (en) Compounds
UA83862C2 (ru) Производные тиазола как модуляторы рецепторов канабиноидов
MY147640A (en) Bicyclic amides as kinase inhibitors
ATE355374T1 (de) Therapeutische agentien und methoden ihrer verwendung zur behandlung von amyloidogenen erkrankungen
HK1080459A1 (en) Novel pyrimidineamide derivatives and the use thereof
SE0002729D0 (sv) Novel compound form
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
SE9903997D0 (sv) New compounds
SE0102055D0 (sv) New Compounds
DE69834500D1 (de) Xanthinderivative zur behandlung von hirnischämie
SE0102440D0 (sv) New compound
DE60035429D1 (de) Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
MXPA04005809A (es) Inhibidores de proteinas quinasas.
MXPA06007007A (es) Derivados de prolina usados como ingredientes farmaceuticos activos para el tratamiento de tumores.
SE0102057D0 (sv) New Salts I
MXPA05014143A (es) Derivados de cumarina para el tratamiento de trastornos oftalmicos.
DE602004022783D1 (de) Heterozyklische harnstoff-derivate für die behandlung von schmerzen.
RS51316B (sr) Nova upotreba (r)-(-)-2-/5-(4-fluorofenil)-3- piridilmetilaminometil/-hromana i njegovih fiziološki prihvatljivih soli
SE0102058D0 (sv) New Salts II
TW200509915A (en) Novel oxazoles, their manufacture and use as pharmaceutical agents
SE0100295D0 (sv) New compounds